
MPLT Stock Forecast & Price Target
MPLT Analyst Ratings
Bulls say
MapLight Therapeutics Inc. is positioned favorably in the biopharmaceutical sector with its promising product candidate ML-007C-MA, which has shown potential to be a best-in-class M1/M4 agonist, indicating a solid differentiator in the competitive landscape. Phase 1 and preclinical data highlight ML-007C-MA's improved tolerability and dosing convenience compared to existing treatments, alongside statistically significant improvements in sociability and aggression in preclinical models. The favorable outcomes from the ZEPHYR trial further suggest the likelihood of substantial market uptake, reinforcing a positive outlook on the company’s future performance and product pipeline.
Bears say
MapLight Therapeutics Inc faces significant challenges in the competitive schizophrenia market, entering years behind other candidates like KarXT and contending with a low bar for success despite prior blockbuster sales of minimally differentiated antipsychotics. The company’s Phase 3 readout expectations are tempered by clinical trial delays and a higher-risk profile, which heightens skepticism regarding its pipeline's viability. Furthermore, MapLight's current market cap of approximately $800 million, reflecting less than 1x the unadjusted peak sales potential for schizophrenia treatments, raises concerns about its valuation, particularly under adverse scenarios that drastically decrease projected approval probabilities.
This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MPLT Analyst Forecast & Price Prediction
Start investing in MPLT
Order type
Buy in
Order amount
Est. shares
0 shares